For the quarter ending 2025-09-30, CEROW has $3,911,394 in assets. $8,454,556 in debts.
| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash, restricted cash, and cash equivalents | 2,022,072 | 3,302,674 | ||
| Prepaid expenses and other current assets | 531,827 | 443,892 | ||
| Investment in equity securities, at cost | - | 500,000 | ||
| Deferred offering costs | - | 0 | ||
| Total current assets | 2,553,899 | 4,246,566 | ||
| Deferred offering costs, net of current portion | 174,505 | 500,000 | ||
| Operating lease right-of-use assets | 869,538 | 1,072,950 | ||
| Property and equipment, net | 313,452 | 382,806 | ||
| Total assets | 3,911,394 | 6,202,322 | ||
| Accounts payable | 7,077,342 | 6,213,045 | ||
| Accrued liabilities | 340,691 | 365,060 | ||
| Operating lease liability | 931,023 | 934,310 | ||
| Earnout liability | 20,000 | 20,000 | ||
| Deemed dividend common stock liability, 692 shares | 85,500 | 85,500 | ||
| Total current liabilities | 8,454,556 | 7,617,915 | ||
| Operating lease liability, net of current portion | - | 218,308 | ||
| Total liabilities | 8,454,556 | 7,836,223 | ||
| Convertible preferred stock, value-Series CConvertible Preferred Stock | 2,292 | 46,935 | ||
| Convertible preferred stock, value-Series BConvertible Preferred Stock | - | 0 | ||
| Convertible preferred stock, value-Series DConvertible Preferred Stock | 7,408,866 | 7,240,180 | ||
| Convertible preferred stock, value-Series AConvertible Preferred Stock | 1,287,315 | 1,287,315 | ||
| Common stock, value-Common Class A | 150 | 119 | ||
| Stock subscription receivable | - | 78,750 | ||
| Additional paid-in capital | 73,055,709 | 71,311,399 | ||
| Accumulated deficit | -86,297,494 | -81,441,099 | ||
| Total stockholders deficit | -4,543,162 | -1,633,901 | ||
| Total liabilities and stockholders deficit | 3,911,394 | 6,202,322 | ||
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)